Director/PDMR Shareholding

RNS Number : 2424T
AstraZeneca PLC
24 March 2016
 

Transaction by Persons Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

 

On 24 March 2016, the individuals listed below, who are all persons discharging managerial responsibilities, were granted awards over the Company's ordinary shares or American Depositary Shares (ADSs) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Investment Plan (AZIP). Two ADSs equal one ordinary share.

 

 

Name

Shares awarded under AZDBP

Shares awarded under AZPSP

Shares awarded under AZIP

Award price per share

 

Pascal Soriot

 

17,352

 

129,713

 

21,618

 

3923p

 

Marc Dunoyer

 

8,798

 

54,101

 

9,016

 

3923p

 

Sean Bohen

 

1,496

 

78,155

 

 

13,025

 

$28.19

 

Luke Miels

 

2,107

 

30,225

 

5,037

 

3923p

 

The AZDBP award represents the portion of each individual's annual bonus for 2015 that they are required to defer into shares. The shares are subject to a three-year holding period (24 March 2016 to 23 March 2019).

 

The AZPSP award is subject to a combination of performance measures focused on our scientific, commercial and financial performance assessed over a three-year performance period (1 January 2016 to 31 December 2018). The award will vest on the third anniversary of the date on which it was granted, except for awards to Executive Directors, which will be subject to a further two-year holding period before the award vests.

 

The AZIP award is subject to two performance hurdles relating to dividend and dividend cover over a four-year performance period (1 January 2016 to 31 December 2019). The award is subject to a four-year holding period, commencing at the end of the performance period.

 

Details of the performance measures that relate to the AZPSP and AZIP awards can be found in the Directors' Remuneration Report of the AstraZeneca Annual Report and Form 20-F Information 2015 which is available on the Company's website at www.astrazeneca-annualreports.com/2015/.

 

 

 

A C N Kemp

Company Secretary

24 March 2016

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUSASRNUAOUAR

Companies

AstraZeneca (AZN)
UK 100